Artivion (NYSE:AORT) SVP Sells $910,820.70 in Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Artivion Stock Performance

Shares of AORT opened at $21.27 on Thursday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of 88.63 and a beta of 1.26. The stock has a 50 day moving average of $28.16 and a 200 day moving average of $36.44. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in Artivion by 578.4% during the fourth quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock valued at $1,780,000 after purchasing an additional 33,277 shares during the period. Public Sector Pension Investment Board grew its holdings in Artivion by 23.7% during the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock valued at $6,858,000 after purchasing an additional 30,989 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after acquiring an additional 141,030 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Artivion by 338.2% in the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after acquiring an additional 94,312 shares during the period. Finally, Kennedy Capital Management LLC boosted its holdings in shares of Artivion by 19.0% in the third quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after acquiring an additional 70,030 shares during the period. 86.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AORT has been the subject of a number of research analyst reports. Stifel Nicolaus set a $45.00 price target on Artivion in a research report on Monday, June 1st. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $36.00 price target on shares of Artivion in a research report on Tuesday. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Citizens Jmp reduced their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.